A universal flu vaccine does not exist yet, but scientists have demonstrated that its creation is possible. This optimism comes from experts like Dmitry Lioznov, director of the Influenza Research Institute, who notes that breakthroughs can be expected in the near future. He points to ongoing efforts around the world and across Russia, underscoring that the path to a broad, long-lasting solution is being actively pursued by researchers in many laboratories.
According to Lioznov, several centers are pursuing a universal vaccine, yet none has achieved final success. Some candidates have reached advanced stages of testing, but results have not met expectations. He highlighted that the most recent studies publicly discussed occurred in Israel in 2021, where an initial prototype did not prove effective. Since then, he has clarified that the field remains hopeful and that work continues toward a viable solution.
“Scientists are pushing hard on this front, and there is serious motivation behind the effort”, the professor said. The approach involves targeting the most conserved parts of the influenza virus to stimulate a durable immune response. The theory is that a vaccine could provide protection covering three to five years, reducing the need for frequent reformulations. This line of inquiry is backed by theoretical justification and ongoing experimental work, with many teams aiming to validate it in real-world settings.
Readers can explore further about which flu vaccines currently show the strongest immunogenic profile, other respiratory viruses under investigation in Russia, and the trajectory of new vaccines in the ongoing report by Lioznova at socialbites.ca. This context helps frame how close the scientific community might be to a long-sought universal vaccine, and what it would mean for public health strategies in Canada and the United States. While it is clear that Russia has already deployed vaccines for COVID-19 and influenza trials, the global push continues across continents as researchers compare findings, share data, and refine their approaches through successive clinical phases. The news landscape emphasizes that progress is incremental, with each study building toward a safer and broader protection for people everywhere, including North American populations.